A vaccine for malaria

New England Journal of Medicine

Volumn 365, Issue 20, 2011, Pages 1926-1927

  White, Nicholas J ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; ARTESUNATE; MALARIA VACCINE;

ANTIMALARIAL DRUG RESISTANCE; COST EFFECTIVENESS ANALYSIS; DRUG FEVER; DRUG SURVEILLANCE PROGRAM; EDITORIAL; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MENINGITIS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SEIZURE; VACCINE PRODUCTION;

EID: 81455159337     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1111777     Document Type: Editorial

References (5)

1. Malaria: initiative for vaccine research (IVR). Geneva: World Health Organization (http://www.who.int/vaccine-research/Malaria/en/index.html).
2. The RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011;365:1863-75.
3. Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008;359:2521-32.
4. Asante KP, Abdulla S, Agnandji S, et al. Safety and efficacy of the RTS,S/AS01(E) candidate malaria vaccine given with expanded-programme-on- immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis 2011;11:741-9.
5. Olotu A, Lusingu J, Leach A, et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis 2011;11:102-9.